Biological effects of progestins in breast cancer

Gynecological Endocrinology

Volumn 13, Issue SUPPL. 4, 1999, Pages 11-19

  Pasqualini, J R ^a   Ebert, C ^b  

^a Hormones and Cancer Research Unit   (France)

^b Solvay Pharmaceuticals GmbH   (Germany)

Author keywords

17 Hydroxysteroid dehydrogenase; Breast cancer; Progestins; Sulfatase; Sulfotransferase

Indexed keywords

AROMATASE; ESTRADIOL; GESTAGEN; HYDROXYSTEROID DEHYDROGENASE; SULFOTRANSFERASE;

BREAST TUMOR; ENZYMOLOGY; FEMALE; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW;

17-HYDROXYSTEROID DEHYDROGENASES; AROMATASE; BREAST NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; PROGESTINS; SULFOTRANSFERASES;

EID: 0345132373     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/713602594     Document Type: Article

References (72)

1. Segaloff A. Hormones and mammary carcinogenesis. In McGuire WL, ed. Breast Cancer 2: Advances in Research and Treatment. New York: Plenum Press, 1978:1-22
2. Kirschner MA. The role of hormones in the development of human breast cancer. In McGuire WL, ed. Breast Cancer 3: Advances in Research and Treatment, Current Topics. New York: Plenum Press, 1979:199-226
3. Henderson B, Ross R, Bernstein L. Estrogens as a cause of human cancer: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1988;48:246-53
4. Raam S, Robert N, Pappas CA, et al. Defective estrogen receptors in human mammary cancers: their significance in defining hormone dependence. J Natl Cancer Inst 1988;80:756-61
5. Fuqua SAW, Fitzgerald SD, Chamness GC, et al. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 1991;51:105-9
6. McGuire WL, Chamness GC, Fuqua SAW. Abnormal estrogen receptor in clinical breast cancer. J Steroid Biochem Mol Biol 1992;43: 243-7
7. Castles CG, Fuqua SAW, Klotz DM, et al. Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res 1993;53: 5934-9
8. Murphy LC, Dotzlaw H, Leygue E, et al. Minireview: Estrogen receptor variants and mutations. J Steroid Biochem Mol Biol 1997;62: 363-72
9. Edwards DP, Chamness GC, McGuire WL. Estrogen and progesterone receptors in breast cancer. Biochim Biophys Acta 1979;560:457-86
10. Litherland S, Jackson IM. Antiestrogens in the management of hormone-dependent cancer. Cancer Treat Rev 1988;15:183-94
11. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990;250:1684-9
12. Cropp CS, Nevanlinna HA, Pyrhönen S, et al. Evidence for involvement of BRCA1 in sporadic breast carcinomas. Cancer Res 1994;54: 2548-51
13. Wooster R, Neuhauson SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994; 265:2088-90
14. Loriaux DL, Ruder HJ, Lipsett MB. The measurement of estrone sulfate in plasma. Steroids 1971;18: 463-72
15. Roberts KD, Rochefort JG, Bleau G, et al. Plasma estrone sulfate levels in postmenopausal women. Steroids 1980;35:179-87
16. Pasqualini JR, Chetrite G, Blacker C, et al. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and post-menopausal breast cancer patients. J Clin Endocrinol Metab 1996;81:1460-4
17. Dao TL, Hayes C, Libby PR. Steroid sulfatase activities in human breast tumors. Proc Soc Exp Biol Med 1974;146:381-4
18. Vignon F, Terqui M, Westley B, et al. Effects of plasma estrogen sulfates in mammary cancer cells. Endocrinology 1980;106:1079-86
19. Tseng L, Mazella J, Lee LY, et al. Estrogen sulfatase and estrogen sulfotransferase in human primary mammary carcinoma. J Steroid Biochem 1983;19: 1413-17
20. Pasqualini JR, Gelly C, Lecerf F. Biological effects and morphological responses to estriol, estriol-3-sulfate, estriol-17-sulfate and tamoxifen in a tamoxifen-resistant cell line (R-27) derived from MCF-7 human breast cancer cells. Eur J Cancer Clin Oncol 1986;22:1495-501
21. Pasqualini JR, Gelly C, Nguyen B-L, et al. Importance of estrogen sulfates in breast cancer. J Steroid Biochem 1989;34:155-63
22. Pasqualini JR, Schatz B, Varin C, et al. Recent data on estrogen sulfatase and sulfotransferase activities in human breast cancer. J Steroid Biochem Mol Biol 1992;41:323-9
23. Perel E, Wilkins D, Killinger DW. The conversion of androstenedione to estrone, estradiol, and testosterone in human breast tissue. J Steroid Biochem 1980;13:89-94
24. Silva MC, Rowlands MG, Dowsett M, et al. Intratumoral aromatase as a prognostic factor in human breast carcinoma. Cancer Res 1989;49: 2588-91
25. Pollow K, Boquoi E, Baumann J, et al. Comparison of the in vitro conversion of estradiol-17β to estrone of normal and neoplastic human breast tissue. Mol Cell Endocrinol 1977;6:333-48
26. Abul-Hajj YJ, Iverson R, Kiang DT. Estradiol 17β-dehydrogenase and estradiol binding in human mammary tumors. Steroids 1979;33:477-84
27. Vermeulen A, Deslypere JP, Paridaens R, et al. Aromatase, 17β-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol 1986;22:515-25
28. Nguyen B-L, Chetrite G, Pasqualini JR. Transformation of estrone and estradiol in hormone-dependent and hormone-independent human breast cancer cells. Effects of the antiestrogen ICI 164,384, danazol, and promegestone (R-5020). Breast Cancer Res Treat 1995;34:139-46
29. Raju U, Blaustein A, Levitz M. Conjugation of androgens and estrogens by human breast tumors in vitro. Steroids 1980;35:685-95
30. Pasqualini JR, Chetrite G, Nguyen B-L, et al. Control of estrone sulfatase activity and its expression in human breast cancer. In Motta M, Serio M, eds. Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects. Amsterdam: Elsevier Science, 1994:257-65
31. Pasqualini JR. Steroid sulphotransferase activity in human hormone-independent MDA-MB-468 mammary cancer cells. Eur J Cancer 1992;28A: 758-62
32. Labrie F, Dupont A, Luu The V, et al. Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer. Eur Urol 1993;24(Suppl 2):94-105
33. MacIndoe JH, with the technical assistance of Woods G, Jeffried L, Hinkhouse M. The hydrolysis of estrone sulfate and dehydroepiandrosterone sulfate by MCF-7 human breast cancer cells. Endocrinology 1988;123:1281-7
34. Pasqualini JR, Gelly C, Lecerf F. Biological effects and morphological responses to estriol, estriol3-sulfate, estriol-17-sulfate and tamoxifen in a tamoxifen-resistant cell line (R-27) derived from MCF-7 human breast cancer cells. Eur J Cancer Clin Oncol 1986;22:1495-501
35. Pasqualini JR, Gelly C, Nguyen B-L, et al. Importance of estrogen sulfates in breast cancer. J Steroid Biochem 1989;34:155-63
36. Pasqualini JR, Schatz B, Varin C, et al. Recent data on estrogen sulfatases and sulfotransferases activities in human breast cancer. J Steroid Biochem Mol Biol 1992;41:323-9
37. Pasqualini JR, Varin C, Nguyen B-L. Effect of the progestagen R5020 (promegestone) and of progesterone on the uptake and on the transformation of estrone sulfate in the MCF-7 and T-47D human mammary cancer cells: correlation with progesterone receptor levels. Cancer Lett 1992;66: 55-60
38. Pasqualini JR, Chetrite G, Nguyen B-L, et al. Control of estrone sulfatase activity and its expression in human breast cancer. In Motta M, Serio M, eds. Sex Hormones and Antihormones in Endocrine-Dependent Pathology: Basic and Clinical Aspects, Amsterdam: Excerpta Medica International Congress Series, Elsevier, 1994:257-65
39. Pasqualini JR, Chetrite G, Le Nestour E. Control and expression of oestrone sulphatase activities in human breast cancer. J Endocrinol 1996;150: S99-S105
40. Pasqualini JR, Nguyen B-L. Estrone sulfatase activity and effect of antiestrogens on transformation of estrone sulfate in hormone-dependent vs -independent human breast cancer cell lines. Breast Cancer Res Treat 1991;18:93-8
41. Prost-Avallet O, Oursin J, Adessi GL. In vitro effect of synthetic progestogens on estrone sulfatase activity in human breast carcinoma. J Steroid Biochem Mol Biol 1991;39:967-73
42. Santner SJ, Santen RJ. Inhibition of estrone sulfatase and 17β-hydroxysteroid dehydrogenase by anti-estrogens. J Steroid Biochem Mol Biol 1993; 45:383-90
43. Pasqualini JR, Ebert C, Chetrite G. Control of estradiol in human breast cancer. Effect of medrogestone on sulfatase, 17β-hydroxysteroid dehydrogenase and sulfotransferases activities in human breast cancer cells. In Birkhauser MH, Rozenbaum H, eds. Proceedings of the IV European Congress on Menopause, Paris: Editions ESKA, 1998:625-33
44. Pasqualini JR, Varin C, Nguyen B-L. Effect of the progestagen R-5020 (promegestone) and of progesterone on the uptake and on the transformation of estrone sulfate in the MCF-7 and T-47D human mammary cancer cells: correlation with progesterone receptor levels. Cancer Lett 1992; 66:55-60
45. Chetrite G, Paris J, Botella J, et al. Effect of nomegestrol acetate on estrone-sulfatase and 17β-hydroxysteroid dehydrogenase activities in human breast cancer cells. J Steroid Biochem Mol Biol 1996;58:525-31
46. Nguyen B-L, Fermé I, Chetrite G, et al. Action of danazol on the conversion of estrone sulfate to estradiol and on the sulfatase activity in the MCF-7, T-47D and MDA-MB-231 human mammary cancer cells. J Steroid Biochem Mol Biol 1993;46: 17-23
47. Carlström K, Doberl A, Pousette A, et al. Inhibition of steroid sulfatase activity by danazol. Acta Obstet Gynecol Scand 1984;123:107-11
48. Evans TRJ, Rowlands MG, Jarman M, et al. Inhibition of estrone sulfatase enzyme in human placenta and human breast carcinoma. J Steroid Biochem Mol Biol 1991;39:493-9
49. Chetrite G, Kloosterboer HJ, Pasqualini JR. Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anticancer Res 1997;17: 135-40
50. Chetrite G, Varin C, Delalonde L, et al. Effect of promegestone, tamoxifen, 4-hydroxytamoxifen and ICI 164,384 on the oestrone sulphatase activity of human breast cancer cells. Anticancer Res 1993; 13:931-4
51. Pasqualini JR, Maloche C, Maroni M, et al. Effect of the progestagen promegestone (R-5020) on mRNA of the oestrone sulphatase in the MCF-7 human mammary cancer cells. Anticancer Res 1994; 14:1589-4
52. Andersson S, Moghrabi N. Physiology and molecular genetics of 17β-hydroxysteroid dehydrogenases. Steroids 1997;62:143-7
53. Isomaa VV, Ghersevich SA, Môaentausta OK, et al. Steroid biosynthetic enzymes: 17β-hydroxysteroid dehydrogenase. Annals Med 1993; 2591-7
54. Penning TM. Molecular endocrinology of hydroxysteroid dehydrogenases. Endocr Rev 1997; 18:281-305
55. Pollow K, Boquoi E, Baumann J, et al. Comparison of the in vitro conversion of estradiol-17β to estrone of normal and neoplastic human breast tissue. Mol Cell Endocrinol 1977;6:333-48
56. Gompel A, Malet C, Spritzer P, et al. Progestin effect on cell proliferation and 17β-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. J Clin Endocrinol Metab 1986;63: 1174-80
57. Prudhomme JF, Malet C, Compel A, et al. 17β-Hydroxysteroid dehydrogenase activity in human breast epithelial cells and fibroblast cultures. Endocrinology 1984;114:1483-9
58. Poutanen M, Moncharmont B, Vihko R. 17β-Hydroxysteroid dehydrogenase gene expression in human breast cancer cells: regulation of expression by aprogestin. Cancer Res 1992;52:290-4
59. Malet C, Vacca A, Kuttenn F, et al. 17β-Hydroxysteroid dehydrogenase (E2DH) activity in T47D cells. J Steroid Biochem Mol Biol 1991;39: 769-75
60. Pasqualini JR, Chetrite G, Nguyen B-L, et al. Estrone sulfate-sulfatase and 17β-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. J Steroid Biochem Mol Biol 1995;53: 407-12
61. Adams EF, Coldham NG, James VHT. Steroidal regulation of oestradiol-17β-dehydrogenase activity of the human breast cancer cell line MCF-7. J Endocrinol 1988;118:149-54
62. Coldham NG, James VHT. A possible mechanism for increased breast cell proliferation by progestins through increased reductive 17β-hydroxysteroid dehydrogenase activity. Int J Cancer 1990;45:174-8
63. Couture P, Thériault C, Simard J, et al. Androgen receptor-mediated stimulation of 17β-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Endocrinology 1993;132:179-85
64. Poutanen M, Isomaa V, Kainulainen K, et al. Progestin induction of 17β-hydroxysteroid dehydrogenase enzyme protein in the T-47D human breast cancer cell line. Int J Cancer 1990; 46:897-901
65. Harris AL, Mitchell MD, Smith IE, et al. Aminoglutethimide in the treatment of advanced postmenopausal breast cancer. Cancer Res 1982;42: 3405-8
66. Coombes RC, Goss PE, Dowsett M, et al. 4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer. Steroids 1987;50:245-52
67. de Jong PC, van de Ven J, Nortier HWR, et al. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor Vorozole. Cancer Res 1997;57:2109-11
68. Miller WR. Aromatase inhibitors. Endocr-Rel Cancer 1996;3:65-79
69. Perel E, Daniilescu D, Kharlip L, et al. Steroid modulation of aromatase activity in human cultured breast carcinoma cells. J Steroid Biochem 1988;29:393-9
70. Godefroi VC, Locke ER, Singh DV, et al. The steroid alcohol and estrogen sulfotransferases in rodent and human mammary tumors. Cancer Res 1975;35:1791-8
71. Adams JB, Philips NS, Hall R. Metabolic fate of estradiol in human mammary cancer cells in culture: estrogen sulfate formation and cooperativity exhibited by estrogen sulfotransferase. Mol Cell Endocrinol 1988;58:231-42
72. Chetrite G, Le Nestour E, Pasqualini JR. Estrogen sulfotransferase activities and its mRNA in various breast cancer cell lines. Effect of the progestin, promegestone (R-5020). J Steroid Biochem Mol Biol 1998;66:295-302